

Rovelizumab

Cat. No.:	HY-P99891
CAS No.:	339086-79-2
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke ^[1] .
In Vitro	Rovelizumab binds CD18 and has activity against CD18-integrin complexes including the CD11b-CD18 heterodimer ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
- [2]. Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16(8):863-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA